ATE148918T1 - Für die co4-bindende domäne von hiv spezifische antikörper - Google Patents
Für die co4-bindende domäne von hiv spezifische antikörperInfo
- Publication number
- ATE148918T1 ATE148918T1 AT90907850T AT90907850T ATE148918T1 AT E148918 T1 ATE148918 T1 AT E148918T1 AT 90907850 T AT90907850 T AT 90907850T AT 90907850 T AT90907850 T AT 90907850T AT E148918 T1 ATE148918 T1 AT E148918T1
- Authority
- AT
- Austria
- Prior art keywords
- hiv
- binding domain
- antibodies specific
- epitope
- antibody
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34295089A | 1989-04-25 | 1989-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE148918T1 true ATE148918T1 (de) | 1997-02-15 |
Family
ID=23344000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90907850T ATE148918T1 (de) | 1989-04-25 | 1990-04-25 | Für die co4-bindende domäne von hiv spezifische antikörper |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0470184B1 (de) |
JP (1) | JPH0768276B2 (de) |
AT (1) | ATE148918T1 (de) |
AU (1) | AU633570B2 (de) |
CA (1) | CA2051107A1 (de) |
DE (1) | DE69029937T2 (de) |
DK (1) | DK0470184T3 (de) |
ES (1) | ES2097759T3 (de) |
WO (1) | WO1990012868A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2070182C (en) * | 1989-12-27 | 2002-12-24 | John Ghrayeb | Chimeric immunoglobulin for cd4 receptors |
US7037496B2 (en) | 1989-12-27 | 2006-05-02 | Centocor, Inc. | Chimeric immunoglobulin for CD4 receptors |
WO1991012021A2 (en) * | 1990-02-13 | 1991-08-22 | Oxford Virology Plc | Therapeutic agents, and intermediates for the synthesis thereof |
AP237A (en) * | 1990-05-29 | 1993-04-29 | Cedars Sinai Medical Center | Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use. |
JPH05262662A (ja) * | 1991-07-15 | 1993-10-12 | Calpis Food Ind Co Ltd:The | Hiv重感染防止剤、抗イディオタイプ抗体作製用抗原及び抗イディオタイプ抗体の製造法 |
US5665569A (en) * | 1991-08-22 | 1997-09-09 | Nissin Shokuhin Kabushiki Kaisha | HIV immunotherapeutics |
EP0629244B1 (de) * | 1992-03-06 | 1996-09-18 | Creagen, Inc. | Pathogen-gerichtete biokatalisatoren |
GB9217124D0 (en) * | 1992-08-13 | 1992-09-23 | Antisoma Ltd | Medical treatment |
WO1995020162A1 (en) * | 1994-01-19 | 1995-07-27 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Peptomers with enhanced immunogenicity |
US5618922A (en) * | 1994-07-25 | 1997-04-08 | Nissin Shokuhin Kabushiki Kaisha | NM03 antibody materials and methods |
US6428790B1 (en) | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US5843882A (en) | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
US7048935B2 (en) | 1995-04-27 | 2006-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US6780847B2 (en) | 1995-04-27 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
US6193982B1 (en) | 1995-04-27 | 2001-02-27 | The United States Of America As Represented By The Department Of Health & Human Services | Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120 |
US6987096B1 (en) | 1995-04-27 | 2006-01-17 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof |
JP2933159B2 (ja) * | 1996-03-18 | 1999-08-09 | 株式会社椿本チエイン | 直線作動機のリミットスイッチ取付構造 |
JP4307841B2 (ja) | 2001-03-22 | 2009-08-05 | アメリカ合衆国 | グリコシル化抵抗性シアノビリン及び関連コンジュゲート、組成物、核酸、ベクター、宿主細胞、非グリコシル化シアノビリンの製造方法及び使用方法 |
CN103282385A (zh) * | 2010-11-12 | 2013-09-04 | 美国洛克菲勒大学 | 用于hiv治疗的融合蛋白 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987007616A1 (en) * | 1986-06-12 | 1987-12-17 | Biogen N.V. | Peptides involved in the pathogenesis of hiv infection |
DE3855869T2 (de) * | 1987-02-20 | 1997-10-02 | Genentech Inc | Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern |
ATE122237T1 (de) * | 1987-05-29 | 1995-05-15 | Tanox Biosystems Inc | Hiv-1 neutralisierende monoklonale antikörper. |
EP0339504A3 (de) * | 1988-04-26 | 1990-09-12 | The Du Pont Merck Pharmaceutical Company | Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen |
AU6523590A (en) * | 1989-09-22 | 1991-04-18 | Idec Pharmaceuticals Corporation | Novel peptides associated with the cd4 binding region of gp120 and their methods of use |
-
1990
- 1990-04-25 CA CA002051107A patent/CA2051107A1/en not_active Abandoned
- 1990-04-25 DE DE69029937T patent/DE69029937T2/de not_active Expired - Fee Related
- 1990-04-25 AU AU55536/90A patent/AU633570B2/en not_active Ceased
- 1990-04-25 EP EP90907850A patent/EP0470184B1/de not_active Expired - Lifetime
- 1990-04-25 JP JP2507112A patent/JPH0768276B2/ja not_active Expired - Fee Related
- 1990-04-25 WO PCT/US1990/002261 patent/WO1990012868A1/en active IP Right Grant
- 1990-04-25 ES ES90907850T patent/ES2097759T3/es not_active Expired - Lifetime
- 1990-04-25 AT AT90907850T patent/ATE148918T1/de not_active IP Right Cessation
- 1990-04-25 DK DK90907850.3T patent/DK0470184T3/da active
Also Published As
Publication number | Publication date |
---|---|
JPH04506004A (ja) | 1992-10-22 |
EP0470184A4 (en) | 1992-10-07 |
AU5553690A (en) | 1990-11-16 |
WO1990012868A1 (en) | 1990-11-01 |
DK0470184T3 (da) | 1997-03-10 |
DE69029937T2 (de) | 1997-05-28 |
JPH0768276B2 (ja) | 1995-07-26 |
DE69029937D1 (de) | 1997-03-27 |
ES2097759T3 (es) | 1997-04-16 |
CA2051107A1 (en) | 1990-10-26 |
AU633570B2 (en) | 1993-02-04 |
EP0470184A1 (de) | 1992-02-12 |
EP0470184B1 (de) | 1997-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE148918T1 (de) | Für die co4-bindende domäne von hiv spezifische antikörper | |
BR9305435A (pt) | Processo para determinação de peptídeos correspondendo a epítopos imunologicamente importantes e seu uso em um processo para determinação de anticorpos ou peptídeos biotinilados correspondendo a epítopos imunologicamente importantes, processo para preparação dos mesmos e composições contendo os mesmos | |
BR0210598A (pt) | Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie | |
ATE397014T1 (de) | Hiv-peptide, antigene und impfstoffzusammensetzungen | |
SE9102976L (sv) | Hybrid dna vektorer, encelliga organismer och bakterier till anvaendning foer produktion av hiv-proteiner och peptider | |
WO2002064615A3 (en) | Monoclonal antibodies to human immunodeficiency virus and uses thereof | |
DE3853779T2 (de) | Hiv-1 neutralisierende monoklonale antikörper. | |
NZ224581A (en) | Hiv-2 peptide, aids vaccine | |
WO1991004273A3 (en) | Novel peptides associated with the cd4 binding region of gp120 and their methods of use | |
OA08652A (fr) | Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus HIV et procédés de production de ces anticorps et de diagnostic de la présence de ce virus. | |
DE68926499T2 (de) | Synthetisches antigen zum bewirken einer anti-hiv-reaktion | |
OA09802A (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus. | |
DE3855134T2 (de) | Monoklonale menschliche antikörper gegen hiv-i | |
DE69013950D1 (de) | Monoklonaler Antikörper zur Unterscheidung HIV-2-seropositiver von HIV-1-seropositiven Individuen. | |
SE9000333D0 (sv) | Monoklonal antikropp | |
BRPI9709524B8 (pt) | processo para a produção de um anticorpo para células t que expressam cd4 | |
DE69128108T2 (de) | Monoklonaler Antikörper gegen HTLV-III (Stamm MN) | |
NO175846C (no) | Fremgangsmåte for å oppnå et immunogen | |
ES2195200T3 (es) | Construccion de peptidos de rama multiples. | |
SE8701765D0 (sv) | Analysis method and means therefor | |
AU4832097A (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
ATE134649T1 (de) | Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern | |
DK0569428T3 (da) | Fremgangsmåde til diagnosticering in vitro af HIV-1-virusinfektioner | |
WO1995007465A3 (en) | USE OF ANTIBODIES AGAINST β-2 MICROGLOBULIN-FREE, CLASS I HLA MOLECULES TO PROVIDE HIV DIAGNOSTIC TESTS AS WELL AS COMPOSITIONS HAVING A PROTECTIVE ACTION AGAINST HIV INFECTIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |